Inspire Veterinary Partners (IVP) Plunges Over 60%, Then Rebounds as Nasdaq Delisting Deadline Hits Today

On Thursday, November 20, 2025, Inspire Veterinary Partners, Inc. (Nasdaq: IVP) sits at the center of one of the most volatile micro‑cap stories on the market, with its stock whipsawing after a Nasdaq delisting notice and a critical appeal deadline that falls today. ^[1]

After collapsing more than 58–62% on Wednesday to near its 52‑week low following news of the delisting threat, IVP has bounced sharply in Thursday’s pre‑market and intraday trading — but remains a tiny, highly speculative name fighting to keep its Nasdaq listing. ^[2]

IVP Stock Today: Violent Rebound After a Brutal Sell‑Off

By early afternoon on November 20, IVP shares were trading around $0.15, having changed hands between roughly $0.113 and $0.188 intraday, on extremely heavy volume of over 200 million shares.

That follows:

Wednesday, Nov. 19: IVP fell about 58% to $0.112, with an intraday range as low as $0.105, close to its 52‑week low and far below a 52‑week high around $6.31. Turnover reportedly surged more than 1,300% as traders reacted to the delisting news. ^[3]
Thursday pre‑market: IVP appeared on Benzinga’s list of health‑care movers, up roughly 35% to $0.14 before the opening bell. ^[4]

Online, IVP has become a magnet for high‑risk traders on penny‑stock forums, where some are framing it as a potential short squeeze against the backdrop of the looming delisting. Others explicitly describe it as an “extremely high‑risk gamble” tied to whether the company can stay on Nasdaq. ^[5]

Why Nasdaq Threatened to Delist Inspire Veterinary Partners

The immediate catalyst for this week’s turmoil is a Nasdaq notice of non‑compliance that IVP disclosed in a Form 8‑K filed on November 17, 2025. ^[6]

According to that filing:

On November 13, 2025, Nasdaq notified IVP that its common stock had failed to meet the minimum $1.00 bid price requirement under Listing Rule 5550(a)(2) for 30 consecutive business days. ^[7]
Because IVP has executed multiple reverse stock splits over the past two years with a cumulative ratio of at least 250‑to‑1, the company is not eligible for the standard 180‑day grace period normally given to regain compliance, under Listing Rule 5810(c)(3)(A)(iv). ^[8]
Nasdaq has stated its intention to suspend trading on the Nasdaq Capital Market at the open on November 24, 2025 and file a Form 25‑NSE to remove IVP’s securities from listing and registration, unless the company requests an appeal. ^[9]

Crucially for today:

Appeal deadline: IVP must request a hearing before the Nasdaq Hearings Panel by November 20, 2025, in order to stay any further suspension or delisting action while the hearing is pending. ^[10]

In its 8‑K and related coverage, the company has said it intends to request such a hearing — but has warned that there is no assurance the Panel will grant continued listing or that it can ultimately regain and maintain compliance. ^[11]

As of the public filings available mid‑day Thursday, there has been no separate press release confirming that the appeal has already been submitted; investors are watching closely for any update.

A Look Under the Hood: Q3 2025 Results Show Growth But Ongoing Losses

The delisting drama comes just days after IVP reported its third‑quarter 2025 results on November 12, 2025. ^[12]

Key Q3 2025 highlights (for the quarter ended September 30, 2025):

Total revenue:$4.3 million, up 7% year‑over‑year and 1% sequentially from Q2. ^[13]
Service revenue: About $3.13 million, up 6% vs. Q3 2024. ^[14]
Product revenue: Roughly $1.17–1.2 million, up around 9% vs. the prior year and more than 8% sequentially. ^[15]
Comparable clinic revenue: Increased 9.2% year‑over‑year, driven by stronger appointment utilization and client spending per visit. ^[16]
General & administrative expenses: Fell about 19% vs. Q3 2024, reflecting cost controls and lower consulting spend. ^[17]
Net loss:$2.5 million, an improvement of about 27% compared with a roughly $3.4–3.5 million loss a year earlier. ^[18]
Cash position: Just $341,746 in cash and cash equivalents at September 30, 2025. ^[19]

Management described Q3 as a “solid quarter of continued progress,” pointing to improving clinic economics and cost discipline, as the company works toward eventual profitability. ^[20]

Business Model: Growing Vet Clinic Network with Technology and Pharmacy Upside

Inspire Veterinary Partners is a U.S. pet healthcare services provider that owns and operates a network of veterinary hospitals across multiple states, focused on companion animal care. ^[21]

Recent strategic initiatives include:

Clinic footprint & growth:
- By Q2 2025, IVP operated 14 clinics, including five locations in Florida. ^[22]
- An exclusive, non‑binding Letter of Intent to acquire a New Jersey animal hospital is expected to add about $2 million in annual revenue and expand the network to 15 hospitals across 10 states if completed as planned in Q4 2025. ^[23]
Technology (AI integration):
In June 2025, IVP announced a strategic partnership with Covetrus to roll out an AI‑enabled practice management platform across all clinics, automating medical note‑taking and other workflows. The company estimates this can save veterinarians several hours per week per doctor and standardize KPIs across the network. ^[24]
Online pet pharmacy:
On October 22, 2025, IVP announced plans to launch an online pet pharmacy in Q1 2026, offering both prescription and over‑the‑counter products. The rollout will start in select geographies and is expected to expand nationally through 2026, leveraging existing clinic relationships and supplier ties. ^[25]

These initiatives aim to position IVP as a technology‑enabled consolidator in the fragmented veterinary services market — but they require capital at a time when the balance sheet is under pressure.

Capital Structure: Reverse Splits, Financing Deals and a Tight Cash Position

IVP’s current predicament with Nasdaq can’t be separated from its capital structure and history of corporate actions:

Reverse Stock Splits

On January 22, 2025, IVP announced a 1‑for‑25 reverse stock split, effective January 27, 2025, specifically intended to regain compliance with the $1 minimum bid rule. ^[26]
In its latest 8‑K, Nasdaq notes that IVP has carried out one or more reverse splits over the past two years with a cumulative ratio of 250‑to‑1 or greater, which under Rule 5810(c)(3)(A)(iv) disqualifies the company from receiving another standard grace period to fix its bid‑price deficiency. ^[27]

That history helps explain why Wednesday’s delisting headlines triggered such a violent market reaction: high‑ratio reverse splits are often interpreted by investors as a sign that underlying business challenges have not been solved organically.

Equity & Debt Financing

To keep funding operations and growth, IVP has tapped several financing sources in 2025:

Up to $10 million convertible preferred deal (August 2025):
The company entered a securities purchase agreement for up to $10 million in financing via convertible preferred stock at $1.00 per share, with an initial tranche of about $6 million in cash and transferred securities and the option for up to $4 million more. Proceeds are earmarked for working capital, acquisitions, and shoring up shareholders’ equity for Nasdaq purposes. ^[28]
Senior Convertible Promissory Note (November 5, 2025):
A recent Senior Convertible Promissory Note, executed November 5, 2025, adds another layer of convertible debt to the capital stack, with typical default, acceleration and conversion provisions found in high‑risk micro‑cap financings. ^[29]
Equity compliance win (August/September 2025):
On September 2, 2025, IVP announced that it had regained compliance with Nasdaq Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million, resolving a prior notice dated April 10, 2025. ^[30]

That equity win has now been overshadowed by the separate bid‑price deficiency, which operates under different Nasdaq rules and is driving the current delisting risk.

Earnings Trend: Improving Metrics, But Losses Persist

Looking at the last two quarters together:

Q2 2025:
- Revenue: $4.3 million, down 2% year‑over‑year but up 20% sequentially.
- Comparable clinic revenue: +5.7% vs. prior year.
- Net loss: $3.0 million, a 10% improvement year‑over‑year.
- Cash: approximately $0.2 million at June 30, 2025. ^[31]
Q3 2025:
- Revenue: $4.3 million, +7% year‑over‑year, +1% sequentially.
- Net loss: $2.5 million, 27% narrower vs. Q3 2024.
- Cash: $341,746. ^[32]

Operationally, IVP has shown steady revenue stabilization and loss reduction, but those improvements are taking place against a very tight liquidity backdrop and a tiny market capitalization (around $1 million as of recent data). ^[33]

Market and Analyst Sentiment: Deeply Bearish, With Speculative Trading

Analyst and data‑driven services reflect the risk profile now hanging over IVP:

TipRanks summarizes Nasdaq’s notice and highlights the November 24 suspension date and November 20 appeal deadline, noting that the most recent analyst rating on IVP is “Sell” with a $0.50 price target, while its AI “Spark” model rates the stock “Underperform.” ^[34]
Panabee and Trendonify both frame the situation as an “imminent suspension” story driven by the cumulative reverse split history and the loss of the usual bid‑price grace period, emphasizing that even a hearing only buys time and requires a credible compliance plan to succeed. ^[35]
Quant and trading sites like AInvest detail just how far the stock has fallen — trading at a tiny fraction of its 52‑week high — and characterize the technical setup as severely oversold following Wednesday’s collapse. ^[36]

Meanwhile, retail discussion boards are split between traders hunting for a high‑risk bounce and users warning that the delisting clock makes IVP strictly speculative. ^[37]

What Happens Next? Key Dates and Catalysts to Watch

For anyone following Inspire Veterinary Partners over the coming days and months, several milestones stand out:

November 20, 2025 – Appeal deadline (today):
Last day for IVP to request a hearing before the Nasdaq Hearings Panel to stay the planned suspension and Form 25‑NSE delisting move. ^[38]
November 24, 2025 – Scheduled Nasdaq suspension:
If no appeal is filed (or if Nasdaq otherwise proceeds), trading in IVP shares on the Nasdaq Capital Market is scheduled to be suspended at the open, with a Form 25‑NSE filed to remove the listing. Even with an appeal, the company ultimately must convince the Panel it has a realistic path back to compliance. ^[39]
Q4 2025 / early 2026 – Fundamental drivers:
- Progress on the New Jersey hospital acquisition and overall clinic footprint. ^[40]
- Execution and early metrics for the Q1 2026 online pet pharmacy launch. ^[41]
- Future earnings reports and liquidity updates, which will be critical given the company’s small cash balance and ongoing net losses. ^[42]

If IVP ultimately loses its Nasdaq listing, the shares would likely transition to an over‑the‑counter (OTC) market, which typically involves lower liquidity, wider spreads and reduced institutional participation — factors that can further pressure already volatile micro‑cap stocks.

What Today’s News Means for Investors

For now, Inspire Veterinary Partners sits at the intersection of:

A real operating business that is growing revenue, integrating AI into veterinary workflows and preparing a new online pharmacy; and ^[43]
A stressed capital structure, razor‑thin liquidity and a Nasdaq delisting threat made more acute by a history of large reverse splits. ^[44]

That combination explains why IVP has become both:

A headline‑driven, high‑volatility trading vehicle for short‑term speculators, and
An increasingly challenging long‑term proposition, given the uncertainty around its listing status, financing needs and ability to achieve sustainable profitability. ^[45]

Anyone considering the stock should treat it as high risk, recognize that prices can move dramatically in either direction on news about the Nasdaq process, and understand that this article is for informational purposes only, not personalized investment advice.

How to Read a Balance Sheet to Vet Profitable Stocks